Furthermore, in a series of 124 patients with newly diagnosed MM or primary amyloidosis, it has been shown that patients with CD24 expression (with a cut-off level of 5% on PCs at diagnosis) have a median PFS of 36.2 months, compared to 22.8 months for patients with lower expression levels (p = 0.002) [57]. This evidence concerns the gene CD24 and Miyoshi myopathy.